ClinicalTrials.gg
CompletedNCT06062472Updated Oct 16, 2024

Effect of Lactobacillus Paracasei PS23 on Improving Aging and Muscle Loss in the Elderly

An interventional study of Probiotics and heat-treated of Lactobacillus paracasei HT-PS23 in Elderly, Muscle Loss and Depression, sponsored by Chi-Chang Huang. Completed at 1 site in Taiwan. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Chi-Chang Huang · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Muscular Atrophy with a site in Taiwan — 1 open to participants now, 3 under way, 1 of them phase 3. Muscular Atrophy · Taiwan.

Enrollment
8th of 22
119 · median 100
Started
2023
the only one that year
No phase
13 of 23
1 open now
Registered
20th of 23
by date
Lead sponsor
1 of 23
Chi-Chang Huang

Among the 23 studies in Muscular Atrophy with a site in Taiwan, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2023, is one of 13 with no phase, and was the 20th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

1 of the 23 studies in Muscular Atrophy with a site in Taiwan is open now. Recruiting first, the newest first:

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Atrophy with a site in Taiwan, or all of them as a file.
02

Study summary

This study refers to the supplementation of PS23 in human experiments to help the elderly maintain muscle mass, delay muscle loss, promote physical activity, and delay the occurrence of disability and debilitation in elderly people.

Read the detailed description

Taiwan has become an aging society in recent years. There are important issues to attenuate aging and activate the potential capacity of elderly population. The physical function of middle-aged and older people will degenerate with age and produce age-related diseases. Common symptoms are organ function deterioration, and old age disability caused by malnutrition and muscle loss is also a common care problem. Therefore, how to prevent the complications of muscle loss is one of the important ten years of geriatric research. Although past research has been confirmed, it can improve the debilitating condition of the elderly through nutrition counseling and exercise intervention. However, there is not much in-depth discussion on how probiotics can improve muscle loss and delay symptoms in elderly people. Therefore, this study refers to the supplementation of PS23 in human experiments to help the elderly maintain muscle mass, delay muscle loss, promote physical activity, and delay the occurrence of disability and debilitation in elderly people. One hundred and twenty elderly people will be recruited and then divided into three groups with 40 people in each group: (A) placebo group, (B) PS23 probiotic group, (C) PS23-HT prebiotic group, supplemented for 12 weeks. The diet record, functional test and muscle mass will be carried out every six weeks after the start, to understand whether PS23 is effective in improving muscle loss and weakness in elderly people.

03

Conditions studied

  • Elderly
  • Muscle Loss
  • Depression
  • Anxiety
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 65 and 85 years old

Exclusion criteria

Exclusion Criteria:

  • Have taken antibiotics within one month or are receiving antibiotic treatment
  • Have used probiotic products in powder, capsule or tablet form within two weeks (except for yogurt, yogurt, Yakut and other related foods)
  • People allergic to lactic acid bacteria products
  • Patients diagnosed with stroke or hypertension (systolic blood pressure greater than 139, diastolic blood pressure greater than 89)
  • Exclusion of limbs and hips that have been replaced with artificial joints
  • Persons with incapacity/insufficient decision-making ability
  • Who has been determines that it is not suitable to participate in the research.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Probiotics

    Probiotic capsules contain 10 billion CFU (colony forming units) of Lactobacillus paracasei, 2 caps daily use

    Dietary Supplement: Probiotics

  • Experimental
    Heat-Treated Probiotics

    heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use

    Dietary Supplement: heat-treated of Lactobacillus paracasei HT-PS23

  • Placebo comparator
    Placebo

    The placebo capsule contains microcrystalline cellulose, 2 caps daily use

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotics

    Lactobacillus paracasei PS23 will be used in this study

  • Dietary supplementheat-treated of Lactobacillus paracasei HT-PS23

    heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use

  • Dietary supplementPlacebo

    The placebo capsule contains microcrystalline cellulose, 2 caps daily use

06

What researchers measure

Primary outcomes

  1. muscle mass

    Use dual-energy X-ray absorptiometry, DXA (Lunar iDXA, GE Healthcare, IL, USA) for no-entry measurement to determine muscle mass

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  2. 30 seconds chair stand test

    30 seconds chair stand test will be used as a self-test. Number of stands will be counted.

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  3. Grip strength

    Use the armed grip machine to measure, hold each of the left and right hands three times until they are weak, and record the maximum value

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

Secondary outcomes

  1. Generalized Anxiety Disorder 7-Item, GAD-7

    The GAD-7 Anxiety Questionnaire involves 7 items assessing how often participants have felt bothered by anxiety-related problems over the past two weeks. Each item is rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0-21; where 0-4 = minimal anxiety; 5-9 = mild anxiety; 10-14 = moderate anxiety; 15-21 = severe anxiety

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  2. Geriatric Depression Scale, GDS

    It consists of 30 questions questioning the mood in the last week. This short form consists of 15 questions questioning the mood of the patient. The answers are given according to the feelings in the last week; The answers are "yes" or "no" and 1 point is given for "yes" or "no" answers depending on the question. For the long form: Normal 0 - 10, Mild 11 - 20, Moderate to Severe 21 - 30.For the short form: Normal 0 - 4, Mild 5 - 9, Moderate to Severe 10 - 15.

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  3. Q-LES-Q

    Participants who receive app-CBT will have greater improvement on quality of life, assessed using The Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (Q-LES-Q). The Q-LES-Q-SF is a self-report measure of subjective quality of life, containing Likert items ranging from 1 (Very Poor) to 5 (Very Good). Total scores are presented as a percentage of the maximum value (i.e., ranging from 0 to 100, with higher scores indicating greater quality of life).

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  4. Visual Analogue Scale for GI symptoms, VAS-GI

    Visual Analogue Scale for GI symptoms, VAS-GI (visual analogue scale, VAS 0-10) was designed to measure the response of symptoms and well-being in patients after taking probiotics

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  5. PGI-C

    The PGIC is a scale participants use to rate the level of change they have experienced following treatment. The PGIC is a 7-point scale from 1 (very much better) to 7 (very much worse).

    Time frame: From Baseline to 12 Weeks Assessed

  6. 10 meter walk

    Use a pyramid and a measuring tape to measure a distance of ten meters, and ask the subject to stand up from the chair, go around the pyramid and sit down, and record the time

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  7. fat percentage

    Use dual-energy X-ray absorptiometry, DXA (Lunar iDXA, GE Healthcare, IL, USA) for no-entry measurement to determine fat percentage

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  8. One-leg stance test

    To evaluate static balance ability

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  9. Get Up and Go test

    To evaluate functional walking ability

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  10. Sit and Reach Test

    To evaluate lower-limb strength and flexibility

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  11. Cardiorespiratory fitness

    2-min step test to assess the functional capacity of the respiratory and cardiovascular systems

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  12. Safety assessment - AST

    Safety is assessed function of liver and kidney such as AST (8-38 IU/L).

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  13. Safety assessment - ALT

    Safety is assessed function of liver and kidney such as ALT (4-44 IU/L)

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  14. Safety assessment - Bun

    Safety is assessed function of liver and kidney such as Bun (6-20 mg/dl)

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  15. Safety assessment - Creatinine

    Safety is assessed function of liver and kidney such as Creatinine (0.6-1.3 mg/dl)

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  16. Stress assessment - difference of Testosterone level

    To assess inflammation indicators, used commercial kit human Testosterone (Cayman, Mich, USA) and Elisa reader (PerkinElmer, Massachusetts, USA) for analysis Male 265-923 (in ng/dl) Female 15-70 (in ng/dl) for 19 years and older

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  17. Difference in Oxidative stress - blood level of HSCRP

    To assess inflammation indicators, used commercial kit human CRP (Cayman, Mich, USA) and Elisa reader (PerkinElmer, Massachusetts, USA) for analysis

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  18. Gut microbiota

    Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota in Stool samples before and after probiotics

    Time frame: From Baseline 12 Weeks Assessed

  19. Level of Growth Differentiation Factor-15

    Level of Growth Differentiation Factor-15

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  20. Change in Insulin Sensitivity

    Change in fasting glucose

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  21. The serum IL-6 level

    the measurement of serum IL-6 level in blood

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

  22. TNF-a determination using ELISA

    A serum level of TNF-a was determined by quantitative sandwich enzyme immunoassay (R\&D Systems, Inc., Minneapolis, MN, USA) guided by to the manufacturer's instructions. The intensity of the color was measured at 490 nm.

    Time frame: From Baseline, 6 weeks and 12 Weeks Assessed

07

Study locations

1 site
  • National Taiwan Sport University
    Taoyuan, 333, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Nov 2023, 3 months.

Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 3 months is below that.

Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 2, 2023
StartActual
Aug 8, 2023
Primary completionActual
Nov 30, 2023
CompletionActual
Dec 31, 2023
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06062472
Lead sponsor
Chi-Chang Huang
Collaborators
Bened Biomedical Co., Ltd.
Responsible party
Chi-Chang Huang (Principal Investigator, National Taiwan Sport University) — Sponsor-investigator
First posted
Oct 2, 2023
Start date
Aug 8, 2023
Primary completion
Nov 30, 2023
Completion
Dec 31, 2023
Last update
Oct 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion